Recent News Releases
For investor-related news, see our ASX releases here.
Feb 23, 2023CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates...
- Feb 21, 2023
CSL recognized in Forbes and Statista's Best Large-sized Employer category for the fourth time since 2018. KING OF PRUSSIA, Pa., Feb. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL has...
Feb 20, 2023
HEMGENIX® underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead full lives MARBURG, Germany, Feb. 20, 2023 /PRNewswire/ -- Global...
Feb 6, 2023First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease
First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease
Dec 16, 2022CSL Receives Positive CHMP Opinion for Etranacogene Dezaparvovec – Gene Therapy for Adults with Hemophilia B
Global biotechnology leader CSL (ASX: CSL) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) of etranacogene dezaparvovec.